Form 4: Aligos Therapeutics Director James Scopa Granted Stock Options

Aligos Therapeutics, Inc. Director James Paul Scopa was granted 5,860 stock options with an exercise price of $7.63 per share, vesting over the next year.

Summary

• James Paul Scopa, a Director of Aligos Therapeutics, Inc. (ALGS), was granted 5,860 stock options.
• The stock options have an exercise price of $7.63 per share.
• The grant date for these options was June 25, 2025.
• The options will vest 100% on the earlier of the first anniversary of the grant date (June 25, 2026) or immediately prior to the 2026 annual meeting of the Issuer's stockholders, contingent on continuous service to the Issuer.
• The stock options are set to expire on June 25, 2035.

Sentiment

Score: 6

Explanation: The document reports a routine grant of stock options to a director, which is a standard practice for aligning management interests with shareholders. It does not contain any negative news or significant positive operational updates, hence a neutral to slightly positive sentiment due to incentive alignment.

Positives

• The grant of stock options to Director James Paul Scopa aligns his interests with those of shareholders, incentivizing long-term performance and commitment to the company.

Future Outlook

The vesting schedule indicates that the options will become fully exercisable by June 25, 2026, or prior to the 2026 annual meeting, contingent on the director's continuous service to the company, aligning future incentives.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, used to align executive and director incentives with long-term shareholder value creation and to retain key talent.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice across various industries, including biotechnology, aiming to incentivize long-term commitment and performance.
• The specific number of options and exercise price would typically be benchmarked against peer companies of similar size and stage, though no specific comparable companies or projects are mentioned in this filing.

Related Party Transactions

• The grant of stock options to James Paul Scopa, a Director, constitutes a related-party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align the director's financial interests with those of the shareholders, potentially leading to better long-term performance.

Next Steps

• The stock options are scheduled to vest on the earlier of June 25, 2026, or immediately prior to the 2026 annual meeting of stockholders, subject to continuous service.

Key Dates

Keywords

Aligos Therapeutics, ALGS, SEC Form 4, Stock Options, Insider Transaction, Director Compensation, Equity Compensation, Beneficial Ownership